Prenatal down syndrome screening test > prenatal down syndrome test > Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Prenatal Down Syndrome screening test

Non-Invasive Prenatal Down Syndrome Screening Tests Offer Peace of Mind

One crucial aspect of managing your pregnancy is ensuring that you screen for potential complications and fetal defects including Down Syndrome and Patau Syndrome. As an alternative to invasive methods such as amniocentesis tests for trisomy, Eurofins Biomnis offers prenatal Down Syndrome screening tests that are entirely safe, offering expectant parents peace of mind. This NIPT (non-invasive prenatal testing) procedure draws from a simple maternal blood sample, and offers an accuracy rate of over 99%. By choosing non-invasive prenatal Down Syndrome screening tests, it can be safely determined whether the risk of fetal defects is high or low, potentially avoiding amniocentesis procedures that carry a risk of losing the fetus.

Down Syndrome gets plenty of media attention as a relatively common fetal disorder, but many pregnant women remain unaware of all their options. Scheduling a prenatal Down Syndrome test is an important step toward rule out risks for the syndrome also known as trisomy 21. Non-invasive trisomy 13 tests are also now available, allowing expectant parents to undergo Patau Syndrome screening without the risks associated with traditional and invasive testing methods. Safe, reliable, and rapid, prenatal Down Syndrome tests can be obtained by at-risk expectant mothers starting at the tenth week of pregnancy. They simultaneously detect risks for trisomies 13, 18 and 21, while limiting the need for invasive tests.

To rule out common pregnancy risks, scheduling an NIPT procedure with a primary care physician or other healthcare provider offers patients a safe alternative to invasive tests, including for trisomy 18 screening. The groundbreaking technology developed by Eurofins Biomnis also provides prenatal Down Syndrome screening kits that can be ordered to your physician's practice and carried out there, or at a Eurofins Biomnis partner laboratory. During your consultation, your healthcare provider will prescribe an NIPT and ask you to sign an informed consent form, which is mandatory for all genetic tests. The prenatal Down Syndrome screening procedure is rapid, and results for the test are generally available after 7working days.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%